The rationalisation of goods and services tax (GST), announced on Wednesday, directly lowers the cost of everyday medical consumables, and also high-end therapies in oncology and rare diseases, helping reduce out-of-pocket patient expenditure and better adherence to medication.
The country's largest carmaker Maruti Suzuki India expects auto sales to bounce back to the glory days of 7 per cent growth by FY 27, helped by the proposed GST rate cut which is expected to bring down car prices by 3.5 to 8.5 per cent.
'Despite assurance from China, none of the companies have received supplies from Chinese sellers.'
As the potential threat of a steep 200 per cent tariff on pharmaceutical imports hangs in the air, analysts and industry insiders feel that focus on exports to non-US regions as well as domestic market will increase as a long-term trend. US President Donald Trump told CNBC's Squawk Box in the first week of August that planned tariffs on import of pharmaceutical products to the US could eventually reach up to 250 per cent.
Reliance Industries' refining earnings will remain steady, supported by its position as India's largest importer of Russian crude and favourable global supplies, according to analysts at JM Financial and Goldman Sachs. Reliance imported more Russian barrels than any other Indian refiner in the past eight months, according to data from Bloomberg/Kpler.
Larsen & Toubro Ltd (L&T) is deepening its push into data centres and defence manufacturing while keeping an eye on emerging opportunities in nuclear and thermal power, chairman and managing director SN Subrahmanyan said. The engineering and construction conglomerate has invested around Rs 2,200 crore in data centres, with 32 megawatts (Mw) already operational.
Industry leaders urge India to pursue diplomatic talks with the US, strengthen manufacturing, and consider China ties to gain leverage against tariff pressures.
If pharmaceutical exports from India to the US come under a 25 per cent tariff bracket, the impact on earnings before interest, tax, depreciation and amortisation (Ebitda) could be around 5 per cent, felt analysts. This is after assuming that about 75 per cent of the tariff would be passed on.
Unresolved succession plans and informal ownership structures are fuelling bitter family fights across India's corporate boardrooms.
India's pharmaceuticals and medical devices industries are still hopeful that trade negotiations with the US could cut a fairer deal for both sides, after President Donald Trump announced a 25 per cent tariff rate on India on a social networking platform without divulging the finer details.
Shailesh Jejurikar has 'always made an effort to stay close to his roots.'
Analysts believe Tesla will first focus on building the Model Y brand before expanding -- both in terms of volume and models.
The National Pharmaceutical Pricing Authority will monitor how companies are increasing prices of non-scheduled drugs.
In her letter to the Sona BLW board, Rani Kapur said documents executed by her at a time of "mental and emotional vulnerability" were being misused.
India's mergers & acquisitions (M&As) market recorded deals worth $45.44 billion in the first half of 2025, up nearly 3.3 per cent from a year ago, even as ultra large-ticket transactions remained subdued. During the first half, the 7.1 per cent rise in deal count to 1,614 signals continuing appetite among domestic conglomerates and private equity (PE) funds for mid-sized and smaller assets.
'We realised that partnering with a strong local player like the JSW Group would create far greater value than going it alone.'
Singapore's state investor Temasek Holdings, which recently picked up 10 per cent stake in Haldiram, has been consistently expanding its footprint in India while slowly withdrawing from China over the last three years amid growing geopolitical risks and economic headwinds. India has become Temasek's third-largest market, after Singapore (27 per cent) and China (18 per cent), with its exposure to the country higher than the rest of Asia Pacific excluding the three (11 per cent), according to Temasek's annual review.
Despite the benefits of hybrid technology, a lack of government backing and few launches have kept the segment from gaining ground.
'The reported deal between the European Union and China should mitigate it (shortage) for the medium to long term. Let's wait and watch how this plays out.'
India's fair trade regulator Competition Commission of India (CCI) has launched a formal investigation against India's biggest paints firm, Asian Paints, for alleged abuse of its dominant position in the organised decorative paints market, following a complaint by Aditya Birla group's Grasim Industries' Birla Opus Paints division.
© 2025 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances